K. K. To, O. T. Tsang, W. S. Leung, A. R. Tam, T. C. Wu et al., Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect Dis, issue.20, pp.30196-30197, 2020.

R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange et al., Virological assessment of hospitalized patients with COVID-2019, Nature, 2020.

J. A. Siordia, Epidemiology and clinical features of COVID-19: A review of current literature, J Clin Virol, vol.127, p.104357, 2020.

S. J. Migchelsen, D. L. Martin, K. Southisombath, P. Turyaguma, A. Heggen et al., Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies, PLoS Negl Trop Dis, vol.11, issue.1, p.5230, 2017.

, SARS-CoV-2 diagnostics: performance data. The Foundation for Innovative New Diagnostics (FIND)

L. Guo, L. Ren, and S. Yang, Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19), Clin Inf Dis, 2020.

N. Okba, M. A. Muller, and W. Li, SARS-CoV-2 specific antibody responses in COVID-19 patients, medRxiv, 2020.

F. Amanat, D. Stadlbauer, S. Strohmeier, T. Nguyen, V. Chromikova et al., A serological assay to detect SARS-CoV-2 seroconversion in humans, medRxiv, 2020.

A. T. Huang, B. Garcia-carreras, M. Hitchings, B. Yang, L. Katzelnick et al., A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease, medRxiv, 2020.

M. T. White, J. T. Griffin, and O. Akpogheneta, Dynamics of the antibody response to Plasmodium falciparum infection in African children, J Infect Dis, vol.210, pp.1115-1137, 2014.

P. F. Teunis, J. C. Van-eijkeren, W. F. De-graaf, A. B. Marinovi?, and M. E. Kretzschmar, Linking the seroresponse to infection to within-host heterogeneity in antibody production, Epidemics, vol.16, pp.33-39, 2016.

M. Andraud, O. Lejeune, and . Musoro, Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis A virus, PLoS Comput Biol, vol.8, p.1002418, 2012.

M. T. White, R. Verity, and J. T. Griffin, Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial, Lancet Infect Dis, vol.15, pp.1450-58, 2015.

M. T. White, P. Bejon, and A. Olotu, A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine, BMC Med, vol.12, p.117, 2014.

E. R. Adams, R. Anand, M. I. Andersson, K. Auckland, J. K. Baillie et al., Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. medRxiv, 2020.

A. Hachim, N. Kavian, C. A. Cohen, A. Chin, D. Chu et al., Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients, medRxiv, 2020.

R. J. Longley, M. T. White, E. Takashima, J. Brewster, M. Morita et al., Development and validation of serological markers for detecting recent exposure to Plasmodium vivax infection, Nature Med, 2020.

A. S. Azman, J. Lessler, F. J. Luquero, and T. R. Bhuiyan, Estimating cholera incidence with cross-sectional serology, Sci Transl Med, vol.11, issue.480, 2019.

D. A. Helb, K. K. Tetteh, P. L. Felgner, J. Skinner, A. Hubbard et al., Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities, Proc Natl Acad Sci, vol.112, issue.32, pp.4438-4485, 2015.

R. Perraut, M. L. Varela, C. Loucoubar, O. Niass, A. Sidibé et al., Serological signatures of declining exposure following intensification of integrated malaria control in two rural Senegalese communities, PLoS One, vol.12, issue.6, p.179146, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01635035

J. Hadjadj, N. Yatim, L. Barnabei, A. Corneau, J. Boussier et al., Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients, medRxiv, 2020.

F. X. Lescure, L. Bouadma, D. Nguyen, M. Parisey, P. H. Wicky et al., Clinical and virological data of the first cases of COVID-19 in Europe: a case series, Lancet Inf Dis, issue.20, pp.30200-30200, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02549694

R. J. Longley, C. T. França, M. T. White, C. Kumpitak, P. Sa-angchai et al., Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand, Malar J, vol.16, issue.1, p.178, 2017.

R. N. Kirchdoerfer, N. Wang, J. Pallesen, D. Wrapp, H. L. Turner et al., Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis, Sci Rep, vol.8, issue.1, p.15701, 2018.

K. A. Callow, H. F. Parry, M. Sergeant, and D. A. Tyrrell, The time course of the immune response to experimental coronavirus infection of man, Epidemiol Infect, vol.105, issue.2, pp.435-481, 1990.

L. P. Wu, N. C. Wang, Y. H. Chang, X. Y. Tian, D. Y. Na et al., Duration of antibody responses after severe acute respiratory syndrome, Emerg Infect Dis, vol.13, issue.10, pp.1562-1566, 2007.

P. G. Choe, R. Perera, W. B. Park, K. H. Song, J. H. Bang et al., MERS-CoV antibody responses 1 year after symptom onset, South Korea, Emerg Infect Dis, vol.23, issue.7, pp.1079-1084, 2015.

W. Liu, A. Fontanet, P. H. Zhang, L. Zhan, Z. T. Xin et al., Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome, J Infect Dis, vol.193, pp.792-797, 2006.

H. Mo, G. Zeng, X. Ren, H. Li, C. Ke et al., Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance, Respirology, vol.11, issue.1, pp.49-53, 2006.

W. C. Cao, W. Liu, P. H. Zhang, F. Zhang, and J. H. Richardus, Disappearance of antibodies to SARS-associated coronavirus after recovery, N Engl J Med, vol.357, issue.11, pp.1162-1165, 2007.

V. Yman, M. T. White, M. Asghar, C. Sundling, K. Sondén et al., Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure, BMC Med, vol.17, issue.1, p.22, 2019.

Q. Long, H. Deng, and J. Chen, Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice, MedRxiv, 2020.

R. Lassaunière, A. Frische, Z. B. Harboe, A. Nielsen, A. Fomsgaard et al., Evaluation of nine commercial SARS-CoV-2 immunoassays, medRxiv, 2020.

L. Grzelak, S. Temmam, C. Planchais, C. Demeret, C. Huon et al., SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors, medRxiv, 2020.

R. L. Prentice, Surrogate endpoints in clinical-trials-definition and operational criteria, Stat Med, vol.8, pp.431-471, 1989.

L. Qin, P. B. Gilbert, L. Corey, M. J. Mcelrath, and S. G. Self, A framework for assessing immunological correlates of protection in vaccine trials, J Infect Dis, vol.196, pp.1304-1316, 2007.

M. T. White, O. Idoko, S. Sow, A. Diallo, B. Kampmann et al., Antibody kinetics following vaccination with MenAfriVac and implications for the duration of protection: an analysis of serological data, Lancet Inf Dis, vol.19, issue.3, pp.327-336, 2019.